Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02323230
Title A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors ImmunoVaccine Technologies, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries CAN


No variant requirements are available.